1. A Review of Medtronic CoreValve TAVI Clinical Results:
Focus on Learning Curve Issues and Outcomes
Ganesh Manoharan
MBBCh, MD, FRCP(I), FRCP(Edin)
Consultant Cardiologist, Royal Victoria Hospital
Co-Director, CACR, University of Ulster
Hon. Senior Lecturer, Queens University
Belfast, UK

2. Ganesh Manoharan, MBBCh, MD
Advisory Committee
Boston Scientific Corporation
Cordis Corporation
Consulting Fees
Medtronic, Inc.
Honoraria
St. Jude Medical, Inc.

3. CoreValve Experience
More than 12,000 implants over 30 countries

4. CoreValve Clinical Experience
Study
Study Size
Number of centers
Follow-up to date
Status
18 Fr Safety and Efficacy Trial1
126 9
2 years
Enrollment complete
Australia-New Zealand Study2
375 10
6 months
Enrolling
REDO9 18 4
30 days
Advance Study10
1000
Up to 50 NA
Italian Registry8
772 14
1 year
Enrollment Complete
Belgian Registry5
328 (141 CoreValve)
13 (6 CoreValve)
Spanish Registry3
108 3
French Registry4
244 (78 CoreValve) 16
UK Registry7
872 (460 CoreValve) 25
German Registry6
697 (588 CoreValve) 22
Medtronic Sponsored Studies
Independent Studies
1. Medtronic. Data on file.
2. Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
3. Petronio AS. The Italian CoreValve Registry.
6. Eltchaninoff H. FRANCE Registry: French Aortic National CoreValve and Edwards Registry. Presented at the American Heart Association Scientific Sessions 2009, November 14-18, Orlando, FL.
7. Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
See reference slide for sources.

5. Baseline Patient Characteristics
18 Fr S&E1
ANZ2
Spanish Registry3
French Registry4
Belgian Registry6
German Registry8
UK Registry7
Italian Registry8 N
126
118
108 66
141
588
460
772
Age (years)
81.9 ± 6.4
82.3 ± 7.7
78.6 ± 6.7
82.5 ± 5.9
82 ± 6
81.4 ± 6.4 83
Female
57.1%
40.7%
54.6%
51.5%
56%
55.8%
48%
Logistic EuroSCORE (%)
23.4 ± 13.8
18.4 ± 11.9
16 ± 13.9
24.7 ± 11.2
25 ± 15
20.8 ± 13.3
20.3
22.9 ± 13.5
NYHA Class III and IV
74.6%
83.9%
58.4% –
78%
88.2%
74%
70.6%
LVEF %
51.6 ± 13.1
57.8 ± 13.0
51 ± 15
59 ± 13
52.1 ± 15
51 ± 13
Mean Pressure Gradient (mmHg)
46.8 ± 15.9
50.6 ± 16.2
55 ± 14.3
46 ± 15
49 ± 16
48.7 ± 17.2
52 ± 17
Aortic valve area (cm2)
0.72 ± 0.17
0.71 ± 0.21
0.63 ± 0.2
0.71 ± 0.16
0.63 ± 0.13
0.64 ± 0.18
0.71
Medtronic. Data on file.
Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Patients currently treated with CoreValve are all high risk patients
See reference slide for sources. 5

6. Percent of Patients (%)
Procedural Success
98.1%
97.0%
98.0%
98.7%
99.0%
98.1%
100%
95.8%
83.1% *
80%
60%
Percent of Patients (%)
40%
20% 0%
18 Fr S&E1
ANZ2
Spain3
French4
Belgian5
Germany6
UK7
Italian8
N = 126
N = 118
N = 108
N = 78
N = 141
N = 588
N = 460
N = 772
Procedure Success is not defined consistently across all studies.
* Technical Success is reported here.
1. Medtronic Data on File. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, 2009.
2. Meredith I. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. Transcatheter Cardiovascular Therapeutics 2010, Washington, DC.
3. Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
4. Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
5. Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
6. Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
7. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
8. Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 6

7. Has experience reduced complication rates?

8. Learning Curve - CoreValve The Bern Experience (August 2007 – July 2010) - N=150
First Cohort
(0-75)
Second Cohort
(76-150) % %
CAVE Siegburg – Follow up not completed (analysis for the first 50 patients)
missing data: european, italian, munich, Büllesfeld, germany
Bern 2year fup: 18.6% completed

9. 30-Day All-Cause Mortality
25%
20%
15.2%
15.1%
15%
12.4% %
10%
9.0%
7.4%
7.2%
5.5%
5.6% 5%
Medtronic. Data on file.
Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 0%
18 Fr S&E1 N = 125
ANZ2 N = 118
Spain3 N = 108
French4 N = 66
Belgian5 N = 119
German6 N = 588
UK7 N = 460
Italian8 N = 772
1. Medtronic Data on File. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, 2009.
2. Meredith. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. TCT 2010, Washington, DC.
3. Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
4. Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
5. Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
6. Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
7. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
8. Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 9

10. One-half of all Mortality Occurs Within 30 Days12
100 90 10 80 70 8 60
Number of Deaths 6
% of All Mortality 50 40 4 30 20 2 10 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93
106
113
121
151
171
186
201
225
267
283
294
311
349
502
515
709
1007
Days of follow-up
Petronio, AS. The Italian CoreValve Registry, EuroPCR 2010. 10

11. Percent of Patients (%)
One Year Survival
100%
90%
85.1%
81.6%
79.0%
80%
71.9%
70%
60%
Percent of Patients (%)
50%
40%
30%
20%
10% 0%
Medtronic. Data on file.
Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
18 Fr S&E1 N = 126
Belgian2 N = 141
UK3 N = 460
Italian4 N = 772
Survival rates comparable with octogenarians who have had sAVR or sAVR+CABG5
Survival rates reported are based on Kaplan-Meier Analysis.
1. Medtronic. Data on file. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, 2009.
2. Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
3. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
4. Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
5. Moat, Neal. UK TAVI Registry, TAVI Mid and Long-term Clinical Outcomes. EuroPCR 2010. 11

12. Percent of Patients (%)
Two Year Survival
100%
90%
77.6%
80%
70%
59.7%
60%
Percent of Patients (%)
50%
40%
30%
20%
Medtronic. Data on file.
Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
10% 0%
18 Fr S&E1 N = 126
UK2 N = 460
Survival rates reported are based on Kaplan-Meier Analysis.
1. Gerckens, Ulrich, MD. Safety, Durability and Effectiveness at Two Years with the 18 Fr CoreValve Transcatheter Aortic Valve. EuroPCR 2010.
2. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 12

13. 30-Day Stroke Rate Stroke Rate at 30 days 20% 15% 10% 5% 0%
9.6%
10% 5%
4.5%
4.0%
4.0%
2.6%
1.9%
1.7% 0%
18 Fr S&E*1 N = 125
ANZ2 N = 118
French3 N = 66
Belgian4 N = 119
German5 N = 588
UK6 N = 460
Italian7 N = 772
Stroke is not defined consistently across all studies
*Stroke is defined as permanent neurologic defects, included patients who had reversible neurologic events if there was structural evidence of an intracranial event
Medtronic. Data on file. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, 2009.
Meredith. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. TCT 2010, Washington, DC.
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 13 13

14. Post-Procedure Aortic Regurgitation0% 0% 0%
0.3%
100% 0% 2% 6%
8.6%
90%
15.2%
24.1%
80%
42.9%
AR grade 4
70%
52%
60%
AR grade 3
54.9%
46.3%
Percent of Patients (%)
50%
AR grade 2
40%
AR grade 1
30%
39.0%
None
20%
42%
27.8%
27.6%
10%
9.5% 0%
18 Fr S&E1# N = 84
ANZ2# N = 105
Spanish2* N = 108
German3*† N = 689
# Measured with echo
*Measured with angiography
†German registry data includes both patients treated with CoreValve, 84.5%, and EDW Sapien, 15.5%
Gerckens, Ulrich, MD. Safety, Durability and Effectiveness at Two Years with the 18 Fr CoreValve Transcatheter Aortic Valve. EuroPCR 2010.
Meredith. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. TCT 2010, Washington, DC.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Zahn, et al. Transcatheter Aortic Valve Implantation: First Results from Multi-center Real World Registry. EHJ [epub ahead of print].

15. Residual AR has an Impact on In-hospital Mortality20 18
P < 0.001 16
14.1 14 12
In-hosptial Mortality % 10 8
5.9 6 4 2
Residual AI 0-I (82%)
Residual AI ≥ II° (18%)
Zahn R. The German TAVI Registry, EuroPCR 2010.

16. Proper Implant Location Results in Less ParaValvular Leak35
P = 0.09
P = 0.19
P = 0.05 30
P = 0.10 25 20
Good
Grade >1 Paravalvular Leak (%)
Suboptimal 15 10 5
1 mo
3 mos
6 mos
12 mos
N = 326
Proper implant location defined as 4 to 8 mm below annulus.
De Carlo. Serial Echocardiographic Evaluation of the CoreValve Aortic Bioprosthesis: Italian Registry EuroPCR 2010.

17. Vascular Complications
30%
25%
19.5%
20%
Percent of Patients (%)
15%
9.5%
10%
7.5%
6.7%
6.5% 5%
3.9% 0%
18 Fr S&E1* N = 125
ANZ2# N = 118
French3† N = 66
German4‡ N = 588
UK5§ N = 460
Italian6|| N = 772
Medtronic. Data on file.
Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Vascular complication is not defined consistently across studies.
*Defined as arteriovenous fistula, bowel ischemia, hematoma, pseudoaneurysm, and retroperitoneal bleed.
#Defined using proposed VARC definitions, Serruys EuroPCR Includes both major (1.9%) and minor complications (4.6%).
†Definition unknown.
‡Defined as groin problems, including major and minor.
§Defined as major vascular injury or later vascular injury requiring surgery.
||Defined as severe bleeding/surgery of femoral access.
Medtronic. Data on file. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, 2009
Meredith. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. TCT 2010, Washington, DC.
Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Zahn, et al. Transcatheter Aortic Valve Implantation: First Results from Multi-center Real World Registry. EHJ [epub ahead of print.
Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 17

18. Pacemaker Implantation Varies Between Studies
Procedural variability, anatomical
differences and clinical practice
variation impact pacemaker
implant rates:9,10
Depth of implant may induce conduction disturbances11
Valvuloplasty balloon size may impact conduction system11
Anatomical and patient-related factors may impact conduction disturbances12
Inter-hospital variability due to physician subjectivity, country-based healthcare norms and reimbursement strategies9
New Pacemaker Implants at 30 days
Weighted Average 28.5%
Weighted Average 28.5%
Weighted Average 28.5%
60%
60%
60%
50%
50%
50%
42.5%
42.5%
42.5%
40%
40%
40%
40%
40%
40%
35.2%
35.2%
35.2%
31.3%
31.3%
31.3%
Percent of Patients (%)
Percent of Patients (%)
Percent of Patients (%)
30%
30%
30%
26.9%
26.9%
26.9%
26%
26%
26%
23%
23%
23%
18.5%
18.5%
18.5%
20%
20%
20%
10%
10%
10% 0% 0% 0%
18 Fr S&E1 N = 125
18 Fr S&E1 N = 125
18 Fr S&E1 N = 125
ANZ2 N = 118
ANZ2 N = 118
ANZ2 N = 118
Spain3 N = 108
Spain3 N = 108
Spain3 N = 108
French4 N = 66
French4 N = 66
French4 N = 66
Belgian5 N = 119
Belgian5 N = 119
Belgian5 N = 119
German6 N = 588
German6 N = 588
German6 N = 588
UK7 N = 460
UK7 N = 460
UK7 N = 460
Italian8 N = 772
Italian8 N = 772
Italian8 N = 772
1. Medtronic Data on File. COR : 18 Fr Safety& Efficacy Study Re-Analysis, August 14, 2009.
2. Meredith IT. A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve® Registry. Transcatheter Cardiovascular Therapeutics 2009, September 21-25, San Francisco, CA.
3. Avanzas P, Munoz-Garcia AJ, Segura J, et al. Percutaneous implantation of the CoreValve® self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010;63:
4. Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
5. Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
6. German Registry data on file. New pacemakers with Corevalve 240/565.
7. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
8. Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.
See Reference slide for sources 1-8
See Reference slide for sources 1-8
See Reference slide for sources 1-8
9. N. Piazza, “AV-Block and Pacemaker Requirements Associated with Medtronic CoreValve TAVI: Incidence, Outcomes and Treatment Strategies”, TCT 2009.
10. Latsios et al. Device Landing Zone” Calcification, Assessed by MSCT, as Predictive Factor for Pacemaker Implantation after TAVI. Catheter Cardiovasc Interv [Epub ahead of print].
11. N. Piazza, “AV-Block and Pacemaker Requirements Associated with Medtronic CoreValve TAVI: Incidence, Outcomes and Treatment Strategies”, TCT 2009.
12. N. Piazza, “Persistent Conduction Abnormalities and Requirments for Pacemaking 6 Months after TAVI”, PCR 2010. 18 18

19. Pacemaker Implantation Varies by Center
Italian Registry – Pacemaker Implantation Rate by Center
50%
Average Pacemaker Implantation Rate 18.5%
45%
40%
36.2%
35.7%
35.0%
35%
32.3%
30%
24.1%
Pacemaker Implantation Rate (%)
25%
21.4%
18.6%
18.2%
20%
14.7%
15.4%
14.9%
15%
11.1%
10%
3.7% 5% 0%
Legnano
Mirano
Pisa, University
Brescia, H. Civile
Milano, Niguarda
Padova, University
Catania, University
Roma, S. Camillo
Firenze, Careggi
Milano, S. Ambrogio
Firenze, University
Milano, S. Raffaele
Bologna, University
Petronio, AS. The Italian CoreValve Registry, EuroPCR 2010.

20. Is TAVI outcome related to Euroscore?

21. CoreValve Australia-New Zealand Study Baseline Characteristics
Mean ± SD, or %
Age (years)
82.3 ± 7.7
Logistic EuroSCORE (%)
18.4 ± 11.9
STS (%) (Mortality)
5.6 ± 2.7
Female
40.7%
NYHA
Class I: 0.0%
Class II: 16.1%
Class III: 62.5%
Class IV: 21.4%
Aortic valve area (cm2)
0.71 ± 0.21
Peak gradient (mmHg)
81.5 ± 23.6
Mean gradient (mmHg)
50.6 ± 16.2
LVEF (%)
57.8 ± 13.0

22. CoreValve Australia-New Zealand Study 30-Day All-Cause Mortality
25%
20%
15.2%
15.1%
15%
12.4% %
10%
9.0%
7.4%
7.2%
5.5% 5%
5.6% 0%
18 Fr S&E N = 125
ANZ N = 118
Spain2 N = 108
French1 N = 66
Belgian1 N = 119
German1 N = 588
UK1 N = 460
Italian1 N = 772

23. CoreValve Clinical Portfolio
Evaluate Long-term Performance & QOL
Evaluate Procedural Best Practices
Evaluate Performance in Expanded Patient Populations
18 Fr Safety & Efficacy
ADVANCE II Study
SURTAVI
ANZ Study
REDO
ADVANCE Study
US Pivotal Extreme Risk (Inoperable) Cohort
US Pivotal High Risk
Surgical Cohort

24. Conclusions (1)
TAVI with the Medtronic CoreValve is safe and effective
Continued improvements in technique, understanding patient selection (clinical and technical suitability) and post procedural management impacts on outcome
Continued emphasis on teaching, training and dissemination of information will impact on outcome

25. Conclusions (2)
Standardisation of event reporting (VARC) will allow more transparent comparisons to be made
Technological iterations will further enhance the safety and efficacy of this technique
Long term durability and outcome awaited